WTR Healthcare Happenings

In this episode, Christer Rosen, Founder and CEO of Jupiter Neurosciences (Nasdaq: JUNS), and President & COO Alison Silva join Water Tower Research’s Tim Gerdeman and Healthcare Analyst Robert Sassoon to discuss Jotrol, the company’s proprietary micellar formulation of resveratrol engineered to overcome long‑standing bioavailability and tolerability limitations. Jotrol has demonstrated a ninefold increase in resveratrol bioavailability, enabling therapeutic exposure without the high‑dose GI side effects that have historically constrained the molecule’s therapeutic potential.

The team highlights progress on the active Phase 2A Parkinson’s trial enrolling at Georgetown University, designed to evaluate safety, PK, and neuroinflammatory biomarkers, with data expected in early 2027. Management also outlines Jupiter’s dual‑engine strategy spanning clinical development, a consumer longevity brand, and new licensing initiatives including ALA‑002.

In this episode of Healthcare Happenings, Robert Sassoon, WTR healthcare equity analyst, joins host Tim Gerdeman to discuss his initiation of coverage on NurExone Biologic (TSXV: NRX / OTCQB: NRXBF), a preclinical biopharma company advancing a novel exosome platform targeting CNS regeneration. Sassoon walks through the science behind exosome therapeutics, NurExone's differentiated ExoTherapy platform and lead asset ExoP10, which combines a natural exosome carrier with an RNA payload designed to silence the P10 gene and unlock nerve regeneration in acute spinal cord and optic nerve injury. The conversation also covers the company's vertical integration strategy through its Exotop subsidiary and U.S. master cell bank, the LOI with Florida-based BioXTech for GMP manufacturing capacity, and the key milestones investors should track, including IND submission, compassionate use access, first commercial exosome revenue, and a potential U.S. mainboard listing. 

In this episode of Healthcare Happenings, Nick Kadysh, Founding CEO and President of PharmAla Biotech (CSE: MDMA / OTCQB: MDXXF), joins host Tim Gerdeman and WTR healthcare analyst Robert Sassoon to discuss two recently announced transactions. The first is the formation of Restora Neuroscience, a special purpose vehicle created to advance APA01, a non-controlled neurology molecule, through a preclinical partnership with Datiba. The second is a term sheet with Jupiter Neurosciences for the exclusive U.S. licensing of ALA-002, PharmAla's next-generation MDMA therapeutic, in a deal valued at over $100 million in potential milestones and royalties. The conversation covers deal structure, partner selection, key investor milestones across both transactions, and how this partnership-driven model allows PharmAla to advance its pipeline while maintaining its position as a leading global supplier of clinical-grade MDMA. 

In this special episode of the WTR Healthcare Happenings podcast, the second in a two-part series, Professor David Nutt, Chief Science Officer of Solvonis Therapeutics (LSE: SVNS), talks to host Tim Gerdeman and WTR analyst Robert Sassoon about addiction and why he believes Solvonis' novel approach offers potentially better solutions than are currently available. The discussion also covers persistently low AUD treatment penetration, the favorable UK regulatory and reimbursement outlook versus US payer dynamics, how ketamine compares with emerging GLP-1 and psilocybin approaches, and the advantages of Solvonis' AI-enabled drug discovery platform. Finally, Nutt shares his thoughts on where the US federal addiction-research community actually is on psychedelic-assisted treatment for AUD and stimulant use disorder, following his recent presentation at the NIH ( National Institutes of Health) CRAN (Collaborative Research on Addiction) joint council as the sole external speaker on psychedelic therapy for addictions.

In this special episode of Healthcare Happenings, the first in a two‑part series, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company’s strategy in addiction and psychiatry — a field with significant unmet need and limited effective treatment options. Anthony walks through SVN‑001, a ketamine‑based therapy for severe alcohol use disorder now in Phase 3 in the UK, and SVN‑002, a U.S.-focused program targeting the much larger moderate‑to‑severe alcohol use disorder market. He also explains why Solvonis may not yet be fully recognized compared to its U.S.-listed peers. 

Stay tuned for Part 2 next week with Professor David Nutt, Chief Scientific Officer of Solvonis, who unpacks the neuroscience behind SVN‑001, the search for a better MDMA, and where psychedelic‑assisted addiction therapy is headed.

In this episode of Healthcare Happenings, John Lai, CEO of PetVivo Holdings (PETV), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company's regenerative medicine platform for companion animals. The conversation covers PetVivo's product suite led by Spryng, its cartilage-mimicking protein particle matrix; the off-the-shelf Precise PRP product; and a BioPiezo collaboration with the University of Connecticut that pairs Spryng with nanofiber technology to drive cartilage regeneration with potential translation to human medicine. Lai also previews the launch of PetVivo.ai, an agentic AI platform for veterinary practices, and outlines the company's pathway toward cash-flow breakeven. 

 In this episode of the WTR Healthcare Happenings podcast, Stephen Rodgers, Head of Global Planning and Strategy at SBC Medical Group Holdings (NASDAQ: SBC), joins WTR’s Tim Gerdeman and Robert Sassoon. Rodgers discusses how SBC’s 26‑year build‑out into a 283‑location platform serving 2.1 million customers with a 72% repeat rate has created a scale, data, and trust advantage that competitors have been unable to replicate. He outlines the rationale for expanding beyond aesthetics into orthopedics, fertility, and dentistry, and highlights longevity as a major white space being addressed through the SBC Wellness 2.0 B2B program. The conversation also covers SBC’s partnership‑driven global expansion via Orange Twist in the U.S., AHH in Singapore, and footholds in Thailand and Vietnam, and concludes with Rodgers’ perspective on AI as a key driver—including plans to leverage SBC’s proprietary library of millions of before‑and‑after treatment images. 

ExoZymes (NASDAQ: EXOZ) CEO Michael Heltzen joins Tim Gerdeman and Robert Sassoon in this episode of the WTR Healthcare Happenings podcast to discuss the company’s AI-driven, cell-free biomanufacturing platform and how it aims to overcome longstanding scalability challenges in synthetic biology. The conversation covers the scientific differentiation of its “exozyme” enzyme engineering approach, the commercial strategy behind its lead programs in metabolic health (NCT) and non-intoxicating cannabinoids, and the broader opportunity to produce high-value molecules that have historically been inaccessible at scale. The podcast also explores regulatory dynamics, near-term commercialization milestones, and ExoZymes’ dual strategy of advancing internal assets while positioning the platform for future licensing, alongside considerations around capital efficiency and funding.

On the latest WTR Healthcare Happenings podcast, we were joined by David Sans, PhD, a healthcare investment banker, and our host, Tim Gerdeman, WTR’s Vice-Chair, Co-Founder, and Chief Marketing Officer. Over the past two years, Sans has focused on a corner of the market most investors overlook: publicly listed companies with low or negative shareholders’ equity and stock prices trading below $1. The conversation covered the tightening Nasdaq listing environment, the mechanics of strategic asset acquisitions and structured financing, the shift in M&A toward asset-level transactions, and a compelling new instrument—clinical trial insurance—that is opening the door to a new class of biotech investors. 

On this episode, Vivos Therapeutics (NASDAQ: VVOS) CEO Kirk Huntsman joins WTR’s Tim Gerdeman and Robert Sassoon on Healthcare Happenings to discuss the company’s 2025 results and the momentum behind its shift from a dentist‑led model to a medically integrated strategy centered on sleep centers and physician referrals, anchored by the Sleep Center of Nevada acquisition. Huntsman highlights strong validation of the new model despite temporary 4Q25 staffing and payer delays, which are now largely resolved. The conversation covers improving patient treatment conversion, infrastructure expansion, rising cardiology and hospital referrals tied to OSA risk, and Vivos’ path toward cash‑flow breakeven by end‑2026.